文献速递毛发、甲与色素性疾病

皮秒翠绿宝石激光联合衍射透镜阵列与三联霜治疗亚洲女性黄褐斑的随机对照试验

Prospective randomized controlled trial comparing treatment efficacy and tolerance of picosecond alexandrite laser with a diffractive lens array and triple combination cream in female asian patients with melasma.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-10-17

三组MASI评分在第12周和第20周均显著改善,第20周改善率分别为53%、38%和50%。皮秒激光联合DLA与三联霜疗效相当,激光组在纹理、斑点、皱纹和毛孔方面有改善。

要点

  • 皮秒翠绿宝石激光联合DLA治疗黄褐斑的疗效与三联霜相当。
  • 激光组在皮肤纹理、斑点、皱纹和毛孔方面观察到改善。
  • 伴有毛细血管扩张的黄褐斑患者可能受益于额外激光治疗次数。

核心结论

  • 皮秒翠绿宝石激光联合DLA治疗亚洲女性黄褐斑的疗效与三联霜相当。

主要发现

  • A1、A2和B组分别有9、11和6例完成研究。
  • 三组MASI评分在第12周和第20周均显著改善,第20周改善率分别为53%、38%和50%。
  • VISIA分析显示3次激光后斑点、卟啉、毛孔和棕斑显著改善(P < 0.05)。
  • A2组在斑点、皱纹和毛孔方面改善优于A1组,但仅红色区域差异显著(P < 0.001)。
  • 三组所有副作用均为暂时性,在1-3个月后逐渐消退。

关键数值与推荐

  • MASI评分改善率:A1组53%,A2组38%,B组50%(第20周)。
  • VISIA分析中斑点、卟啉、毛孔和棕斑改善的P值均小于0.05。
  • A2组与A1组仅红色区域差异有统计学意义(P < 0.001)。

临床怎么用

  • 皮秒翠绿宝石激光联合DLA可作为亚洲女性黄褐斑的治疗选择,疗效与三联霜相当。
  • 对于伴有毛细血管扩张的黄褐斑患者,可考虑增加激光治疗次数。
  • 激光治疗相关副作用为暂时性,通常在1-3个月内消退。

局限性

  • 每组完成研究的样本量较小(A1组9例、A2组11例、B组6例)。
  • A1组和A2组在第20周随访期分别为3个月和1个月,随访时间不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent evidence suggests melasma to be a photoaging disorder. Triple combination creams (TCC: fluocinolone acetonide 0.01%, hydroquinone 4% and tretinoin 0.05%) remain the gold standard treatment. Picosecond alexandrite laser treatment using a diffractive lens array (DLA) has been identified to be effective for improving photoaging conditions. OBJECTIVE: We aimed to compare the efficacy and tolerance of the picosecond alexandrite laser with those of DLA and TCC in female Asian patients with melasma. METHODS: Twenty-nine patients were randomly assigned to group A1 (3 laser sessions at 4-week intervals), A2 (5 laser sessions at 4-week intervals) or B (TCC daily for at least 8 weeks and then tapered until the final evaluation). The Melasma Area, Severity Index (MASI) score and VISIA were assessed at baseline, week 12 and week 20. By week 20, the follow-up periods for groups A1 and A2 were 3 months and 1 month, respectively. RESULTS: Nine, 11 and 6 participants in groups A1, A2 and B completed the study, respectively. MASI scores were significantly improved in all 3 groups at weeks 12 and 20. In groups A1, A2 and B, the improvement rates at week 20 were 53%, 38% and 50%, respectively. VISIA® analysis additionally revealed a significant improvement in spots, porphyria, pores and brown spots after 3 laser sessions (P < 0.05). Group A2 showed greater improvements than group A1 in terms of spots, wrinkles and pores; however, only red areas were significantly different (P < 0.001). All side-effects in the 3 groups were transient and gradually subsided after 1-3 months. CONCLUSION: Picosecond alexandrite laser treatment using DLA showed comparable efficacy with TCC for the treatment of melasma. Improvements in texture, spots, wrinkles and pores were observed in the laser groups. Patients with melasma lesions that exhibit telangiectasia may benefit from additional laser treatment sessions.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Wang YJ, Lin ET, Chen YT, et al. Prospective randomized controlled trial comparing treatment efficacy and tolerance of picosecond alexandrite laser with a diffractive lens array and triple combination cream in female asian patients with melasma. J Eur Acad Dermatol Venereol. 2019. PMID: 31494973. doi:10.1111/jdv.15934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。